Supported by independent educational grants from Neurocrine Biosciences and Teva Pharmaceuticals.

Quiz: Which Treatment May Significantly Increase the Risk of TD?
A retrospective study involving 7985 veterans found which medication or medication class was associated with the highest risk of tardive dyskinesia?
Tardive Dyskinesia Assessment Still Mandated Despite COVID-19
Despite the impact the COVID-19 pandemic has had on psychiatry practice, a proactive, routine, and systematic assessment for tardive dyskinesia in patients taking antipsychotics is a mandate for all clinicians, Rakesh Jain, MD, MPH, said at Psych…
Reducing Antipsychotic Dosage May Increase Risk of Hospitalization
A study recently published in BMC Psychiatry found that antipsychotic dosage reduction in patients with bipolar and major depressive disorders was associated with an increase in all-cause and mental health-related hospitalizations.
Q&A: Updates From Dr. Rakesh Jain on Managing Tardive Dyskinesia
Psych Congress Steering Committee member Rakesh Jain, MD, MPH, is educating clinicians on the latest research and strategies for treating tardive dyskinesia during the 2020 Psych Congress Regionals meetings. He shares some of his guidance here.
Quiz: Risk Factors for Tardive Dyskinesia
Which of the following is a risk factor for tardive dyskinesia (TD): age, diagnosis of schizophrenia, comorbid bipolar and related disorders, history of extrapyramidal symptoms, or all of these?
Deutetrabenazine Offers Long-Term Benefit for Severe TD
Deutetrabenazine offers long-term benefit for patients with severe tardive dyskinesia (TD), according to results from a 3-year open-label extension trial presented in a poster at Psych Congress 2020.
Adverse Events With Deutetrabenazine Titration Decrease During Maintenance
Adverse events in patients treated with deutetrabenazine were more common during titration than maintenance, a finding that provides “important context for the dosing schedule to providers and patients.”
3-Point Drop in AIMS Score Provides Clinically Meaningful Gains in TD
A decrease of 3 points on the Abnormal Involuntary Movement Scale score is the minimal clinically important difference for treatment of tardive dyskinesia with deutetrabenazine, according to a poster presented at Psych Congress 2020. 
In-depth Discussion about Deutetrabenazine and Valbenazine
Drs. Jain and Kumar provide and in-depth analysis of two new VMAT2 inhibitors approved to treat tardive dyskinesia.
Treating Patients With Long-term Tardive Dyskinesia
Is there benefit in treating a patient with a VMAT2 inhibitor if they have already had severe tardive dyskinesia for several years? Find out here.
Does Tardive Dyskinesia Severity Impact the Effectiveness of Treatments?
Are medications for tardive dyskinesia effective in mild, moderate, or severe cases? Get the answer from Psych Congress cochair Rakesh Jain, MD, MPH.
Back to Top